0001563880 2026-08-06 2026-08-06 0001563880 1 2026-08-06 2026-08-06 pure shares iso4217:USD N/A 0001563880 EX-FILING FEES S-8 S-8 Trevi Therapeutics, Inc. false Equity Common Stock, $0.001 par value per share true 8000000 17.97 143760000 0.0001381 19853.26 143760000 19853.26 0 19853.2 <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:4%;box-sizing:content-box;"></td> <td style="width:96%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock, $0.001 par value per share (“Common Stock”), that may from time to time be offered or issued to prevent dilution by reason of any stock dividend, stock split or other similar transaction.</span></p></td> </tr> <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The proposed maximum offering price per unit of $17.97 is estimated pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee, and is based upon the average of the high and low prices of the Common Stock on August 3, 2026, as reported on the Nasdaq Global Market.</span></p></td> </tr> <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consists of 8,000,000</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> additional shares issuable under the Trevi Therapeutics, Inc. Amended and Restated 2019 Stock Incentive Plan.</span></p></td> </tr> </table>